Molecure is a clinical stage biotechnology company, that uses its world leading medicinal chemistry capabilities to discover and develop first in class small molecule drug candidates that directly modulate underexplored protein targets and the function of RNA to treat multiple incurable diseases. Molecure has generated a diverse pipeline of seven distinct programs with the support of leading academic life science institutions globally. Molecure's lead drug candidate is OATD-01, a first-in-class dual chitinase inhibitor for the treatment of fibrotic and inflammatory diseases, including interstitial lung diseases such as sarcoidosis and idiopathic pulmonary fibrosis (IPF). The phase I study was completed in 2022 and the phase II study in sarcoidosis patients started in March 2024. OATD-02 is the first and only dual acting, highly potent arginase inhibitor in cancer development, involved in both tumor immunity and metabolism. In March 2023, Phase 1 clinical trial was initiated. Molecure’s headquarters and laboratories are located in Warsaw, Poland with an additional laboratories in Łódź. The company is listed on the Warsaw Stock Exchange (ticker: MOC).
Company Details
- Employees
- 79
- Founded
- -
- Address
- Zwirki I Wigury 101, Warsaw,mazowieckie 02-089,poland
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- oncoarendi.com
- Keywords
- Small Molecule Drug Discovery, Immuno-oncology, Medicinal chemistry, pharmaceuticals, inflammatory diseases, fibrotic diseases, chitinase, arginase, and Respiratory diseases, Cancer, Immunotherapy, Small molecule immunomodulators.
- HQ
- Warsaw, Mazowieckie
Molecure Questions
Molecure's website is oncoarendi.com
Molecure's LinkedIn profile is https://pl.linkedin.com/company/molecure-sa
Molecure has
79 employees.
View email and phone details for 79
employees at Molecure.
Molecure's industry is
Biotechnology Research
Molecure's top competitors are
Bioinmed,
Pure Biologics,
Celon Pharma S.a.,
Ardigen,
Selvita,
Jjp Biologics,
Ryvu Therapeutics,
Bioton S.a.,
Polpharma Biologics,
Captor Therapeutics Sa.
Molecure's categories are Biotechnology Research
Molecure's founding year is 2012
